Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06744647 · ClinicalTrials.gov registry record · Phase 2

Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation

A Phase 2 study of Kidney Transplantation and Antibody-mediated Rejection, sponsored by Alexion Pharmaceuticals.

Recruiting
Registry status
Phase 2
Development phase
45
Enrollment target
20
Study locations

NCT06744647 is a Phase 2 study of Kidney Transplantation and Antibody-mediated Rejection that is actively recruiting participants, run by Alexion Pharmaceuticals. The registered enrollment target is 45 participants, below the 267-participant average among 33 other Kidney Transplantation trials with a reported enrollment target (83% lower). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06744647, a Phase 2 study of Kidney Transplantation and Antibody-mediated Rejection, is actively recruiting participants, sponsored by Alexion Pharmaceuticals.

RECRUITING
Registry status
Phase 2
Development phase
45 participants
Enrollment target
20
Study locations

Study Summary

The primary objective of this study is to evaluate the efficacy of ALXN2030 compared with placebo on biopsy proven histologic resolution in participants with active or chronic active antibody-mediated rejection (AMR) at Week 52.

Conditions Studied

Kidney Transplantation Antibody-mediated Rejection Biopsy-proven Histologic Scores AMR

Interventions

  • DRUG Placebo
  • DRUG ALXN2030

Study Locations (20)

New York

  • Research Site - New York
  • Research Site - New York
  • Research Site - New York
  • Research Site - New York

California

  • Research Site - Los Angeles
  • Research Site - Orange

Michigan

  • Research Site - Ann Arbor
  • Research Site - Detroit

Texas

  • Research Site - Dallas
  • Research Site - Houston

Alabama

  • Research Site - Birmingham

Arizona

  • Research Site - Scottsdale

Florida

  • Research Site - Tampa

Georgia

  • Research Site - Atlanta

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2025-03-07
Est. Completion 2028-11-07
Phase Phase 2

Sponsor

Alexion Pharmaceuticals

162 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06744647

The ClinicalTrials.gov registry entry for NCT06744647 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 267-participant average among 33 other Kidney Transplantation trials with a reported enrollment target (83% lower). The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Kidney Transplantation appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06744647 reports 20 study locations spanning 14 distinct geographic areas - top geographies include New York, California, Michigan.

Frequently Asked Questions

What is clinical trial NCT06744647 about?

NCT06744647 is a clinical study titled "Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation". The primary objective of this study is to evaluate the efficacy of ALXN2030 compared with placebo on biopsy proven histologic resolution in participants with active or chronic active antibody-mediated rejection (AMR) at Week 52.

What is the current status of trial NCT06744647?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2025-03-07. Estimated completion is 2028-11-07.

What conditions does trial NCT06744647 study?

This clinical trial studies the following conditions: Kidney Transplantation, Antibody-mediated Rejection, Biopsy-proven Histologic Scores, AMR.

What interventions are being tested in trial NCT06744647?

The interventions under investigation include: Placebo (DRUG), ALXN2030 (DRUG).

Who is sponsoring clinical trial NCT06744647?

This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06744647 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Kidney Transplantation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Kidney Transplantation

All registered trials for this condition

Antibody-mediated Rejection

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.